Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2018-02-19 Regulatory Filings
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release ("Communiqué de Presse") dated February 19, 2018, announcing that the company, Pharnext, will participate in a conference organized by F2iC on February 26, 2018. It details the event and provides general company information (pipeline, contacts). This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed investor presentation (IP). It is an announcement about future participation in an industry event, which is a type of general corporate communication. Since there is no specific category for 'Conference Participation Announcement,' and it is a general corporate update/announcement, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general announcement category for non-standard filings, although it is closer to a general press release. Given the options, RNS is the best fit for a general corporate news announcement that doesn't fit the specific financial/governance/legal categories.
2018-02-19 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de Presse" (Press Release) and announces that Pharnext will present the status update of its Phase 3 clinical trial (PLEO-CMT) at a scientific conference (Journées de la Société Francophone du Nerf Périphérique). This is a short announcement detailing an upcoming event where company information will be shared, rather than the full report, transcript, or formal regulatory filing itself. Since it is a press release announcing corporate activity (presentation of clinical trial progress), and it doesn't fit perfectly into ER (Earnings Release) or CT (Call Transcript), it falls best under the general category for regulatory announcements or corporate news that isn't a specific financial report. Given the options, 'RNS' (Regulatory Filings / General regulatory announcements) is the most appropriate fallback for a standard press release announcing scientific/clinical progress, although 'IP' (Investor Presentation) might be considered if the content was the presentation itself. However, as it is an announcement *about* a presentation, RNS is safer, or potentially 'LTR' if the focus was purely on legal/regulatory trial status, but RNS covers general corporate news announcements well.
2018-01-18 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release announcing that an update from a clinical trial (PLEO-CMT) will be presented at a scientific conference (Francophone Peripheral Nerve Society conference). It details the date, time, and topic of the presentation. This type of announcement, which informs stakeholders about upcoming participation in an external event (like a conference presentation or publication), typically falls under general regulatory announcements or investor relations updates. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific legal/director filing, the most appropriate general category is Regulatory Filings (RNS), as it serves as a broad communication to the market about company activities not covered by more specific codes. The document length (3992 chars) is short, but it is an announcement *about* an event, not an announcement *of* a report being attached, which would strongly suggest RPA. Therefore, RNS is the best fit for this type of corporate news update.
2018-01-18 English
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 1% confidence The document is explicitly titled 'Presse Release' and announces that 'Dr. Philippe Chambon joins Pharnext's Board of Directors' and that he is replacing another director. This content directly relates to changes in the company's board of directors and senior management. This matches the definition for Board/Management Information (MANG). The document length is relatively short (3419 chars), but it is a complete announcement, not just a notice that a report is attached, so RPA/RNS is not the primary classification.
2018-01-02 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 1% confidence The document is titled 'Communiqué de Presse' (Press Release) and announces a specific corporate event: the appointment of Dr. Philippe Chambon to the Board of Directors, replacing Jacques Attali. This directly relates to changes in the company's governing body. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is a formal announcement, not a comprehensive report or a transcript. Therefore, MANG is the most appropriate classification.
2018-01-02 French
Pharnext S.A.: Successful Intermediate Analysis for PLEO-CMT Phase III Clinical Trial in Charcot-Marie-Tooth Disease Type 1A
Legal Proceedings Report Classification · 1% confidence The document is a news release dated November 29, 2017, announcing the 'Successful Intermediate Analysis' for a Phase III clinical trial (PLEO-CMT). It details study progress, safety monitoring board conclusions, and future timelines. It is not a full Annual Report (10-K), an Interim Report (IR), or a formal Audit Report (AR). It is an announcement regarding clinical trial progress, which is typically classified as a general corporate/regulatory news item. Since there is no specific category for 'Clinical Trial Updates' or 'Study Results,' and it is a formal announcement disseminated via DGAP (a service often used for regulatory news), the most appropriate fallback category is Regulatory Filings (RNS), as it conveys material, non-financial operational information to the market. The document length (5553 chars) is substantial enough that it is the primary content, not just a link to a report, ruling out RPA.
2017-11-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.